FDA Grants Priority Review to Brepocitinib NDA for Dermatomyositis, Decision Expected Q3 2026
Summary
The FDA has accepted Roivant Sciences' New Drug Application (NDA) for brepocitinib in dermatomyositis and granted it Priority Review, setting a PDUFA target action date in Q3 2026. This is a highly significant positive development, as Priority Review is reserved for drugs that, if approved, would provide significant improvements in the safety or effectiveness of the treatment of a serious condition. If approved, brepocitinib would be the first targeted therapy for dermatomyositis, addressing a substantial unmet medical need and representing a material revenue opportunity for Roivant. The company anticipates a U.S. launch by the end of September 2026 following potential approval. Investors will now closely monitor the PDUFA date for the final regulatory decision.
At the time of this announcement, ROIV was trading at $27.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.1B. The 52-week trading range was $8.73 to $29.20. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.